Oppenheimer Reiterates Outperform on Relay Therapeutics, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating on Relay Therapeutics (NASDAQ:RLAY) but lowered the price target from $33 to $25.

May 06, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer has maintained its Outperform rating on Relay Therapeutics but reduced the price target from $33 to $25.
While the reiteration of an Outperform rating suggests a positive outlook on the company's fundamentals and growth prospects, the reduction in the price target may reflect adjustments in valuation metrics, market conditions, or both. This mixed signal could lead to short-term price volatility as investors reassess their expectations based on the new price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100